In-process research and development, net of accumulated amortization
-
90,506,250
92,226,562
92,800,000
Deferred financing costs
-
169,252
-
-
In-process research and development, net of accumulated amortization
88,785,938
-
-
-
Goodwill
9,346,796
9,346,796
9,346,796
9,346,796
Total other assets
98,170,796
100,060,360
101,611,420
102,184,858
Total assets
142,255,198
132,540,579
140,391,730
130,938,025
Accounts payable
8,037,899
9,453,803
11,021,412
13,693,692
License payable
15,650,000
17,650,000
18,250,000
22,650,000
Accrued expenses
25,913,962
24,138,264
4,693,307
4,190,253
Accrued compensation
1,871,320
3,602,007
3,094,395
3,292,447
Note payable
-
-
1,000,000
1,000,000
Operating lease liability
176,170
171,495
148,006
88,348
Total current liabilities
51,649,351
55,015,569
38,207,120
44,914,740
Deferred tax liability
7,696,443
7,803,790
8,035,000
7,770,760
Notes payable, net of deferred financing fees
6,410,161
-
-
-
Operating lease liability noncurrent
590,787
636,667
681,640
724,925
Total liabilities
66,346,742
63,456,026
46,923,760
53,410,425
Common stock - 0.001 par value 250,000,000 shares authorized 27,452,570 and 18,067,744 shares issued and outstanding at june 30, 2026 and september 30, 2025, respectively
27,452
22,376
22,376
18,068
Additional paid-in capital
343,704,577
329,775,214
326,960,700
306,336,239
Accumulated deficit
-277,118,897
-268,256,054
-247,024,914
-238,804,129
Total citius pharmaceuticals, inc. stockholders equity
66,613,132
61,541,536
79,958,162
67,550,178
Non-controlling interest
9,295,324
7,543,017
13,509,808
9,977,422
Total equity
75,908,456
69,084,553
93,467,970
77,527,600
Total liabilities and equity
142,255,198
132,540,579
140,391,730
130,938,025
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.